Applied DNA Sciences Files 8-K on Financials
Ticker: BNBX · Form: 8-K · Filed: Aug 8, 2024 · CIK: 744452
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: APDN
TL;DR
APDN filed an 8-K, check financials.
AI Summary
Applied DNA Sciences, Inc. filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 50 Health Sciences Drive, Stony Brook, NY.
Why It Matters
This filing provides investors with crucial updates on the company's financial performance and condition, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Applied DNA Sciences, Inc. (company) — Registrant
- 50 Health Sciences Drive (location) — Principal Executive Offices
- Stony Brook, NY (location) — Principal Executive Offices
- August 8, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of Applied DNA Sciences, Inc., and to include Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 8, 2024.
What is the official company name as specified in its charter?
The official company name is Applied DNA Sciences, Inc.
Where are Applied DNA Sciences, Inc.'s principal executive offices located?
The principal executive offices are located at 50 Health Sciences Drive, Stony Brook, NY 11790.
What is the Commission File Number for Applied DNA Sciences, Inc.?
The Commission File Number for Applied DNA Sciences, Inc. is 001-36745.
Filing Stats: 534 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-08-08 16:15:38
Key Financial Figures
- $0.001 — ge on which registered Common Stock, $0.001 par value APDN The Nasdaq Stock Mar
Filing Documents
- tm2421159d1_8k.htm (8-K) — 24KB
- tm2421159d1_ex99-1.htm (EX-99.1) — 118KB
- tm2421159d1_ex99-1img001.jpg (GRAPHIC) — 23KB
- 0001104659-24-087280.txt ( ) — 355KB
- apdn-20240808.xsd (EX-101.SCH) — 3KB
- apdn-20240808_lab.xml (EX-101.LAB) — 33KB
- apdn-20240808_pre.xml (EX-101.PRE) — 22KB
- tm2421159d1_8k_htm.xml (XML) — 3KB
02 Results of Operations and Financial
Item 2.02 Results of Operations and Financial Condition. On August 8, 2024, Applied DNA Sciences, Inc. ("Applied DNA Sciences" or the "Company") issued a press release announcing its results of operations for the three-month period ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. ( d) Exhibits 99.1 Press Release of Applied DNA Sciences, Inc. dated August 8, 2024 regarding results of operations for the three-month period June 30, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 8, 2024 APPLIED DNA SCIENCES, INC. By: /s/ James A. Hayward Name: James A. Hayward Title: President and Chief Executive Officer